Cardiac Arrhythmias and Heart Failure

The use of cardiac implantable electronic devices (CIEDs) has substantially increased in the last

decades. They have a significant impact on reducing morbidity and mortality of patients suffering

from cardiac arrhythmias and heart failure. Several developments of technical issues have appeared

over recent years to improve safety and efficacy. However, their role in daily clinical practice is still

unclear. For instance, different leadless technologies, such as leadless pacemakers, subcutaneous

defibrillators or wearables are only partly or not included in the current guideline recommendations. There are also several attempts to improve clinical response to cardiac resynchronization therapy with multipoint or fusion optimized technologies, it is however not clear which patients really benefit from these.

The same is true for novel conduction system pacing modalities: His-bundle pacing seems to be the

most physiological but manually challenging compared to left bundle branch area pacing, which

latter restores only the physiologic activation of the left ventricle but may be easier to perform. The

classical indications for primary prophylactic ICD are also questioned based on some new study

results, highlighting the need for an improved, more detailed and individual risk stratification for

better patient selection. We have important but somehow controversial study results regarding preventive antibiotic therapy (incremental perioperative antibiotics vs antibiotic-eluting envelope) during CIED implantation. Lead extraction tools are also expanding but randomized controlled trials regarding the best approach are completely missing in this field. The importance of remote monitoring is also constantly growing, especially in the current pandemic times, the best way of patient selection needs however more research.
 

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Nimmi Anna
Journal Manager
Allied Journal of Medical Research
Email: medicalresearch@emedsci.com
https://www.alliedacademies.org/allied-journal-of-medical-research/